Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy
Summary
Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ADMINISTRATION OF GLUTATHIONE TRISULFIDE TO AMELIORATE PERIPHERAL NEUROPATHY
Application US20260097091A1 Kind: A1 Apr 09, 2026
Inventors
Fumito Ichinose, III, Mariko Ezaka, Etsuo Ohshima
Abstract
Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripheral neuropathy (CIPN), e.g., by oral or nasal administration. The methods can be used, e.g., to reduce pain associated with CIPN, or reduce the risk of development of CIPN.
CPC Classifications
A61K 38/063 A61K 31/16 A61K 31/385 A61P 25/02
Filing Date
2023-09-26
Application No.
19113849
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.